{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033476","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.243657+00:00","generated_at":"2026-06-04T13:33:00.704342+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet Bio reports Q4 net loss $29.5M, extends cash runway into 2H 2026; IND cleared for ADI-001 in lupus nephritis","bullets":["Net loss $29.5M ($0.69/share) in Q4 2023 vs $29.9M ($0.72/share) in Q4 2022; full-year net loss $142.7M ($3.31/share) vs $69.8M ($1.70/share).","Cash and equivalents $159.7M at Dec 31, 2023; raised net $91.8M from public offering and $19.3M from ATM in Jan 2024, extending runway into 2H 2026.","FDA cleared IND for ADI-001 in lupus nephritis in Dec 2023; Phase 1 trial initiation expected in Q2 2024 with preliminary data in Q4 2024/Q1 2025.","On track to file IND for ADI-270 in renal cell carcinoma in Q2 2024; Phase 1 clinical data expected in first half of 2025.","Appointed Benjamin Hsu, M.D., Ph.D., as VP Clinical Development - Autoimmune, to lead autoimmune cell therapy programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033476","json":"https://secwatch.observer/filing/0000950170-24-033476.json","markdown":"https://secwatch.observer/filing/0000950170-24-033476.md","text":"https://secwatch.observer/filing/0000950170-24-033476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/0000950170-24-033476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/acet-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:33:00.704342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"605f85b6e127e0817550f8a7832bf3206ac77d49","claim":"Adicet Bio, Inc. reported fourth quarter and year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 was $29.5 million, or a net loss of $0.69 per basic and diluted sh, EPS $0.69 per basic and diluted share.","evidence_excerpt":"On March 19, 2024, Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/0000950170-24-033476-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the three months ended December 31, 2023 was $29.5 million, or a net loss of $0.69 per basic and diluted sh"},{"label":"EPS","value":"$0.69 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}